"The outcome of this study is exciting for us and our patients; we plan on expanding and building upon the results," said Francisco Silva, President of DaVinci Biosciences. "We strongly believe that this an important first step for realizing the therapeutic application of stem cells for treating diseases and injuries such as spinal cord injury in humans."
"Although there have been numerous studies in animals demonstrating the benefits of stem cell treatment for the treatment of spinal cord injury, this is the first published study of its kind, it gives patients the possibility that their quality of life can be improved," said Dr. Paul Sanberg, Director of the Center of Excellence for Aging and Brain Repair at the University of South Florida. A survey of spinal cord injury patients conducted in 2004 illustrates that one of the most important aspects in improving their quality of life would be the ability to control bladder function. Patients involved in DaVinci Biosciences' study regained partial or full bladder function, bladder sensation and/or the active ability to void.
DaVinci Biosciences is currently developing cell-based therapeutics and small molecule compounds for the treatment and cure of paralysis caused by spinal cord injury, amyotrophic lateral sclerosis (ALS) and other human degenerative disorders. In tandem with the Company's advances in cell-based and small molecule therapies, DaVinci Biosciences along with its collaborator has patented a surgical technique for the effective delivery of therapies directly into the spinal cord.
About DaVinci Biosciences
DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through independent research and partnerships with universities, medical research institutions, and hospitals, DaVinci Biosciences continues to discover biological breakthroughs relating to and further improving the treatment of degenerative disorders and injury. DaVinci Biosciences is headquartered in Costa Mesa, California. Patients involved in DaVinci's study can be seen discussing their improved quality of life at: http://bit.ly/DavinciStemCellStudy
. For more information please visit http://www.davincibiosciences.com
About Cell Transplantation Cell Transplantation
publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation
will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Page: 1 2 Related biology news :1
. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma2
. Nicotinic receptors may be important targets for treatment of multiple addictions3
. Emphasis on conifer forests places multiple species at risk4
. For honey bee queens, multiple mating makes a difference5
. Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone6
. New magnetic separation technique might detect multiple pathogens at once7
. The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source8
. Multiple species of bacteria may cause trachoma: Implications for treatment9
. Multiple resource management is focus of new technical report10
. Potential new target for multiple sclerosis therapy11
. Fast AFM probes measure multiple properties of biomolecules or materials simultaneously